Compare Nuscale Power Corporation (SMR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs TG Therapeutics Inc — how do they compare? Nuscale Power Corporation trades at $8.84 (market cap $2.76B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 3× Nuscale Power Corporation's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| SMR | TGTX | |
|---|---|---|
Market Cap | $2.76B | $8.26B |
Sector | Utilities | Health |
52-Week High | $53.43 | $59.06 |
52-Week Low | $7.64 | $26.39 |
Enterprise Value | $1.87B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMR (NuScale Power) trades at $7.96, up 3.2% today but remains in a bearish technical trend. The company shows severe fundamental challenges with negative net income margins exceeding -2,000% and consecutive earnings misses. Despite these losses, analyst consensus remains optimistic with a $12.25 price target representing 54% upside potential, driven by nuclear energy's long-term prospects and the company's first-mover advantage in small modular reactors.
The stock presents a high-risk, high-reward opportunity. While current financials are deeply concerning with massive losses and negative cash flow, the potential nuclear energy renaissance and SMR's regulatory approvals offer substantial upside if commercialization succeeds. Investors face significant execution risk as the company burns cash while attempting to secure its first commercial reactor sale.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
